Functionality of Albumin in the Context of Hemodialysis

Launched by UNIVERSITÄT DUISBURG-ESSEN · Aug 17, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how different aspects of hemodialysis (a treatment for patients with severe kidney disease) affect a protein called albumin in the body. Albumin is important because it helps with detoxifying the blood and managing inflammation, both of which can be challenging for patients on dialysis. The researchers want to see if using different types of dialysis equipment or methods can improve the way albumin works, potentially leading to better health outcomes for patients.

To be eligible for this study, participants need to be at least 18 years old and have been on regular hemodialysis for at least three months. The trial is open to both men and women who meet these criteria. If you decide to participate, you can expect to be involved in an interventional study, which means you’ll be part of a structured treatment plan designed to gather important information about how to improve dialysis care. It’s important to know that certain health conditions may exclude individuals from participating, such as severe liver disease or recent serious infections.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years or older at least 3 month of hemodialysis treatment (3x/week) with constant dialysis treatment regimen
• Exclusion Criteria:
• • Age ≤ 18 years
• • Less than three months of regular (3x/week) hemodialysis treatments or less than 3 treatments/week
• • Acute or chronic liver disease (Child stage A or higher or fulfillment of the of the Kings College criteria)
• • Infusion of commercial human albumin (e.g. in the context of ascites drainage) in the last three months prior to study inclusion
• • Acute or severe chronic infections
• • Acute tumor disease